The specialty data mine: What Canadian industry leaders are doing
July 24, 2019
Share on LinkedIn
To get a pulse on the role of health outcomes data in the industry, 20Sense surveyed four Canadian specialty pharmaceutical leaders. As captured in the table below, these leaders collect data on a spectrum of treatment parameters—and use the information to gain strategic insights for the benefit of stakeholders across the country.
Data forecasts
20Sense was curious about how industry leaders see the role of data evolving in the future. So we asked them: “What do you see as the next innovation or opportunity in health outcomes data collection for the Canadian specialty pharmaceutical industry?” Here’s what they told us.
“Health outcomes data facilitates market access and pay-for-performance models, which are becoming increasingly important for specialty pharmaceuticals, and enables us to respond to patient concerns that could lead them to drop off treatment. We are working on finding creative and efficient ways to capture this data directly from patients—for example, through Bluetooth-enabled wearables and medical apps.”
“Our integrated technology platforms have propelled us into a data-rich world. Within specialty medicine, the high-touch treatment model allows us to capture data at every point along a patient’s journey. The next frontier will be to contextualize and combine disparate data sets to gain deeper insights into the value and drivers of specialty therapies.”
“Health outcomes data only has meaning if it influences decisions. That will be the next big step: connecting the dots between data and decision-making. Clinicians will harness real-world data to guide new patient starts and improve their clinical decision making, and the data will support a rationale for coverage and patient access.”
“There are no limits to the creative ways we can collect and use health outcomes data. As just one example, community and specialty pharmacists can enrol patients in support programs, help them stay engaged in program services, and collect clinical and experiential data. This model will gain further traction as more specialty products are launched.”